This doesn’t mean you should ignore an unsolicited offer — it can be a useful signal that your practice is attractive and that the timing might be right to explore a sale more broadly. But responding to it directly, without running a wider process, generally means leaving value on the table. See Crucial Mistakes to Avoid When Selling Your Medical Aesthetics Practice for more on how unsolicited offers typically play out and how to respond to one without giving up your leverage.
The strongest negotiating position of all comes from having more than one qualified buyer interested at the same time. A single PE platform, however well-intentioned, has no competitive pressure to improve their offer. A curated process that surfaces multiple platform, strategic, and individual buyers creates exactly that pressure — which is the core argument for running a disciplined process rather than negotiating one-on-one with whichever buyer reached out first.
How private equity values med spas follows the same fundamental methodology covered in Med Spa & Medical Aesthetics Valuation: adjusted EBITDA multiplied by a market multiple. What’s different with PE buyers specifically is the platform context — a PE-backed platform is often willing to pay a premium multiple for a practice that fits its acquisition criteria, because the practice becomes worth more once integrated into a larger, more efficient structure. This is the multiple arbitrage dynamic covered in Med Spa EBITDA Multiples: a standalone practice trading at 5x–9x can be acquired into a platform at a premium, sometimes toward 10x–14x, because the platform’s own exit multiple is higher than what any single practice could achieve alone.
Most PE investment in this category flows through a med spa mso structure rather than direct ownership of the clinical entity. In states with corporate practice of medicine (CPOM) restrictions, a licensed provider must retain ownership and clinical authority over the practice entity, while a separate management company — which can be PE-owned — holds the business operations, brand, and non-clinical assets under a management services agreement. This medical aesthetics mso model is why PE ownership in this category often looks structurally different from PE ownership in categories without CPOM restrictions, and it’s a key reason working with an advisor who understands this structure matters when evaluating a platform offer.
The broader private equity medical aesthetics thesis is built around a classic med spa roll up strategy: acquire a founding platform, then add smaller practices as tuck-in acquisitions, capturing efficiencies in marketing, back-office operations, purchasing, and management that individual practices can’t achieve alone. A well-executed roll up typically moves through phases — establishing a platform with strong management and systems, adding tuck-in acquisitions to build density in target markets, professionalizing operations across the combined entity, and eventually exiting the platform itself to a larger buyer at a higher multiple than any individual practice could achieve alone.
Med spa platform investment activity has been dominated by a mix of financial sponsors pursuing exactly this playbook — buy, integrate, professionalize, and either continue acquiring or exit at a higher multiple once the platform reaches meaningful scale. Understanding a specific buyer’s med spa acquisition criteria — are they building a founding platform, adding a tuck-in, or making a first entry into the category — helps you understand not just their price, but their likely post-close plans for your practice, your team, and your brand.
For an owner evaluating a roll-up offer, it’s worth asking directly where the platform is in its own lifecycle. An early-stage platform still building its founding presence may offer more equity upside (since the eventual exit multiple is unrealized and speculative) but also more integration risk. A mature platform with an established track record offers more certainty but potentially less rollover upside. Neither is inherently better — the right fit depends on your own risk tolerance and how involved you want to remain post-close.
Selling med spa to private equity differs from selling to an individual operator in a few consistent ways. Diligence is typically more rigorous and more institutional — expect a dedicated deal team, financial and legal diligence advisors, and a structured process with defined milestones. Deal structure often includes rollover equity, giving you a “second bite” if the platform grows and exits again later, rather than a pure cash-out. And post-close integration plans are usually more developed than with an individual buyer, since PE platforms have typically done this before and have playbooks for onboarding new practices. None of this makes a PE sale better or worse than other buyer types by default — it simply means the process, terms, and post-close experience look different, and worth understanding before you’re mid-negotiation.
Owners considering selling med spa to private equity often focus almost entirely on price and structure, and understandably so — but what happens after close matters just as much to how the experience actually feels. Most platforms bring standardized systems for scheduling, marketing, purchasing, and reporting, which can mean real operational change for your team even when the clinical side of the practice stays largely the same. Staff who valued the informality and direct access to ownership that came with an independent practice sometimes find a platform environment more structured than they’re used to; staff who valued more resources, more marketing support, and clearer career paths often find the opposite is true.
Your own post-close role also varies significantly by deal. Some owners exit entirely at close and hand off day-to-day leadership immediately. Others stay on in a clinical or regional leadership role, particularly when rollover equity is part of the structure and the owner has ongoing incentive to help the platform succeed. Getting explicit about which of these you want — and negotiating it into the agreement rather than assuming it will work itself out — is one of the most consequential and most commonly under-negotiated parts of a PE transaction.
Named active platform sponsors currently acquiring in this category include Princeton Medspa Partners (backed by BC Partners, deployed roughly $120M), AYA Medical Spa, Shore Capital, VSS Capital, and Eagle Merchant Partners. This list of aesthetics private equity firms shifts over time as platforms raise new capital, complete roll-ups, and eventually exit — which is one more reason current, verified buyer information matters more than a static list when you’re actually evaluating offers.
Private equity isn’t the only buyer type worth evaluating, and understanding how a PE offer compares to individual operator or strategic buyer offers helps you judge whether a specific offer is actually competitive. Individual operators typically pay closer to the standalone end of the multiple range and rarely offer rollover equity, but they also bring less integration disruption and often preserve more of the practice’s existing identity and team structure. Strategic buyers — larger regional groups expanding density — sometimes pay premiums comparable to PE platforms when your practice fills a specific geographic or service-line gap in their existing footprint, without necessarily bringing the same institutional diligence rigor as a PE-backed process.
None of this means PE is automatically the best or worst option — it means the “best” buyer depends on what you’re actually optimizing for: maximum price, minimum post-close disruption, ongoing involvement through rollover equity, or a clean, fast exit. A curated process that surfaces offers from multiple buyer types at once is the only reliable way to compare these tradeoffs on real numbers rather than assumptions, and it’s the core reason engaging a dedicated med spa m&a advisor before entertaining any single offer — including an unsolicited one — tends to produce a better outcome than negotiating with one buyer type in isolation.
If you’ve received interest from a platform buyer, or you’re evaluating whether private equity is the right path for your practice, see How to Sell a Med Spa: The Complete Owner’s Guide for the full process, or The Evolution of Consolidation in Medical Aesthetics to weigh a full sale against a platform partnership.